Adrian V S Hill

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population
    Dawn Me Bowdish
    McMaster Immunology Research Centre, McMaster University, Hamilton, ON, L8S 4K1, Canada
    BMC Med Genet 14:47. 2013
  2. pmc Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study
    Joann M McDermid
    Division of Nutritional Sciences, Cornell University, 310 Savage Hall, Ithaca, NY 14853, USA
    BMC Infect Dis 13:48. 2013
  3. pmc Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?
    Regitze L Thøgersen
    European Vaccine Initiative, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 326, 69120 Heidelberg, Germany
    Malar J 10:255. 2011
  4. pmc Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth
    Helen A Fletcher
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    BMC Med Genomics 2:10. 2009
  5. pmc Vaccines against malaria
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX37DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2806-14. 2011
  6. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
  7. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
  8. pmc Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection
    Sean C Elias
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    J Immunol 190:1135-47. 2013
  9. doi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
  10. pmc Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
    Sean C Elias
    The Jenner Institute, University of Oxford, Oxford, UK
    Immunology 141:628-44. 2014

Detail Information

Publications107 found, 100 shown here

  1. pmc Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population
    Dawn Me Bowdish
    McMaster Immunology Research Centre, McMaster University, Hamilton, ON, L8S 4K1, Canada
    BMC Med Genet 14:47. 2013
    ....
  2. pmc Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study
    Joann M McDermid
    Division of Nutritional Sciences, Cornell University, 310 Savage Hall, Ithaca, NY 14853, USA
    BMC Infect Dis 13:48. 2013
    ..The objective of this research was to determine how host iron status measured at HIV diagnosis and genotypes related to host iron metabolism were associated with incident TB...
  3. pmc Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?
    Regitze L Thøgersen
    European Vaccine Initiative, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 326, 69120 Heidelberg, Germany
    Malar J 10:255. 2011
    ..However, funding for malaria vaccines has been substantially reduced in the Seventh Framework Programme compared with earlier Framework Programmes, and without further support the gains made by earlier European investment will be lost...
  4. pmc Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth
    Helen A Fletcher
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, South Africa
    BMC Med Genomics 2:10. 2009
    ..CONCLUSION: Our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to TB induced by vaccination with BCG...
  5. pmc Vaccines against malaria
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX37DQ, UK
    Philos Trans R Soc Lond B Biol Sci 366:2806-14. 2011
    ..The most attractive near-term approach to develop such a product is to combine existing partially effective pre-erythrocytic vaccine candidates...
  6. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings...
  7. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ....
  8. pmc Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection
    Sean C Elias
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    J Immunol 190:1135-47. 2013
    ..We also show that controlled infection with 3D7 strain P. falciparum parasites neither boosts existing 3D7-specific T cell responses nor appears to "immune divert" cellular responses toward the Wellcome allele...
  9. doi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
    ..Our data suggest that T(EM) cells are important as a first line of defense against fast-replicating pathogens such as murine Plasmodium and demonstrate the potential of replication-defective SAd as future malaria vaccines for humans...
  10. pmc Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
    Sean C Elias
    The Jenner Institute, University of Oxford, Oxford, UK
    Immunology 141:628-44. 2014
    ..These CHMI data confirm that mBC and antibody responses can be induced and boosted by blood-stage parasite exposure, in support of epidemiological studies on low-level parasite exposure. ..
  11. pmc CISH and susceptibility to infectious diseases
    Chiea C Khor
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    N Engl J Med 362:2092-101. 2010
    ..The interleukin-2-mediated immune response is critical for host defense against infectious pathogens. Cytokine-inducible SRC homology 2 (SH2) domain protein (CISH), a suppressor of cytokine signaling, controls interleukin-2 signaling...
  12. pmc The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
    Anna L Goodman
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Sci Rep 3:1706. 2013
    ..An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum...
  13. pmc Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 19:2269-76. 2011
    ..Further studies are required to assess whether this strategy can achieve protective efficacy against blood-stage malaria infection...
  14. ncbi request reprint Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation
    Katie L Flanagan
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    Am J Trop Med Hyg 74:367-75. 2006
    ..They further define polymorphic variants able to boost specific Th1, Th2, and possibly Tr1 reactivity...
  15. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
    ....
  16. pmc T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein
    Emily K Forbes
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e44943. 2012
    ..The oligomerization domain of C4 bp can thus adjuvant T cell responses induced by AdHu5 vectors against selected antigens and its clinical utility as well as mechanism of action warrant further investigation...
  17. ncbi request reprint Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses
    Magdalena Plebanski
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, UK
    Immunol Cell Biol 83:307-12. 2005
    ..The induction of sporozoite-specific CD8 T-cell responses without the need for liver stage infection identifies a potentially important mechanism in the development of pre-erythrocytic immunity...
  18. pmc Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
    Kathryn T Whelan
    Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 4:e5934. 2009
    ....
  19. ncbi request reprint Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
    Jenni M Vuola
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    J Immunol 174:449-55. 2005
    ..This difference may be of importance for the protective efficacy of these vaccination approaches against various diseases...
  20. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...
  21. ncbi request reprint A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
    Susanna J Dunachie
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 24:2850-9. 2006
    ..Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months...
  22. doi request reprint Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  23. pmc Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis
    Graham S Cooke
    Wellcome Trust Centre for Human Genetics, University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom
    Am J Respir Crit Care Med 178:203-7. 2008
    ..Tuberculosis remains a major cause of morbidity and mortality in the developing world. A better understanding of the mechanisms of disease protection could allow novel strategies to disease management and control...
  24. pmc Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
    Timothy J Powell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 8:e62778. 2013
    ..BCL2 expression was lower in vaccinated volunteers. These data indicate that antigen specific T cells are a useful additional measure for use in human vaccination or immunization studies...
  25. pmc The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
    Alexander D Douglas
    Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Nat Commun 2:601. 2011
    ..falciparum is a degenerate process involving a series of parallel redundant pathways...
  26. pmc Mannose-binding lectin genotypes: lack of association with susceptibility to thoracic empyema
    Stephen J Chapman
    The Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    BMC Med Genet 11:5. 2010
    ..The possible role of MBL genotypic deficiency in susceptibility to thoracic empyema has not previously been reported...
  27. pmc Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Cell Host Microbe 5:95-105. 2009
    ..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1...
  28. doi request reprint Multiple functions of human T cells generated by experimental malaria challenge
    Stephen M Todryk
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK
    Eur J Immunol 39:3042-51. 2009
    ..This study shows that malaria infection elicits specific Th1 and Th2 effector cells, but concomitant weak central memory and regulatory activity, which may help to explain the short-lived immunity observed...
  29. pmc Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice
    Emily K Forbes
    The Jenner Institute, University of Oxford, Headington, Oxford, United Kingdom
    J Immunol 181:4955-64. 2008
    ..Successful immunization regimes appear to induce Ag-specific cells with abundant intracellular cytokine staining...
  30. ncbi request reprint Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity
    Claire L Hutchings
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 175:599-606. 2005
    ....
  31. pmc Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1
    Sumi Biswas
    The Jenner Institute, University of Oxford, Oxford, Oxfordshire, United Kingdom
    PLoS ONE 6:e20977. 2011
    ..Here we describe the pre-clinical development and optimization of recombinant human and simian adenoviral (AdHu5 and ChAd63) and orthopoxviral (MVA) vectors encoding transgene inserts for Plasmodium falciparum AMA1 (PfAMA1)...
  32. pmc Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1
    Helen A Fletcher
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 26:5269-75. 2008
    ..This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines...
  33. pmc ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 20:2355-68. 2012
    ..These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets...
  34. pmc Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates
    Alexandra J Spencer
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e33555. 2012
    ..This report demonstrates that antigen multimerization using IMX313 is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability...
  35. doi request reprint Comparing human T cell and NK cell responses in viral-based malaria vaccine trials
    Tamara K Berthoud
    Centre for Clinical Vaccinology and Tropical Medicine, Oxford University, Churchill Hospital, Oxford, UK
    Vaccine 28:21-7. 2009
    ..In conclusion, measuring antigen-specific T cells is more meaningful than NK cells in these vaccination regimens...
  36. pmc Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials
    Ansar A Pathan
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 2:e1052. 2007
    ....
  37. pmc CD209 genetic polymorphism and tuberculosis disease
    Fredrik O Vannberg
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1388. 2008
    ..The present study investigates the role of the CD209 -336A/G variant in susceptibility to tuberculosis in a large sample of individuals from sub-Saharan Africa...
  38. ncbi request reprint Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi
    Jodene Fitness
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Am J Trop Med Hyg 71:341-9. 2004
    ..Genetic susceptibility to TB in Africans appears polygenic. The relevant genes and variants may vary significantly between populations, and may be affected by HIV infection status...
  39. pmc Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection
    Alexander D Douglas
    Jenner Institute, University of Oxford, UK
    J Infect Dis 208:340-5. 2013
    ..We find that the parameters estimated by these models are closely correlated, and their predictive accuracy for omitted data points was similar. We propose that future studies include the linear model...
  40. pmc Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial
    Rosalind Rowland
    Jenner Institute University of Oxford, Oxford, UK
    Hum Vaccin Immunother 9:50-62. 2013
    ..We hypothesize that FP85A induced anti-FP9 IgG antibodies with cross-reactivity for MVA85A, which may have mediated inhibition of the immune response to subsequent MVA85A. ClinicalTrials.gov identification number: NCT00653770...
  41. pmc Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
    Ansar A Pathan
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Vaccine 30:5616-24. 2012
    ....
  42. pmc A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine
    David W Porter
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK
    Vaccine 29:7514-22. 2011
    ..There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene...
  43. ncbi request reprint CD8+ T effector memory cells protect against liver-stage malaria
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    J Immunol 187:1347-57. 2011
    ..Thus, we identify persistent CD8 T(EM) populations as essential for vaccine-induced pre-erythrocytic protection against malaria, a finding that has important implications for vaccine design...
  44. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...
  45. ncbi request reprint Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Tuberculosis (Edinb) 85:47-52. 2005
    ..MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed...
  46. pmc Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites
    Karolis Bauza
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Infect Immun 82:1277-86. 2014
    ..Our data indicate that ChAd63 and MVA expressing PvTRAP are good preerythrocytic-stage vaccine candidates with potential for future clinical application...
  47. ncbi request reprint Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming
    Edwin A M Lee
    Molecular Immunology Group, Weatherall Institute of Molecular Medicine, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 36:1168-78. 2006
    ....
  48. pmc Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
    Amy C Boyd
    The Jenner Institute, Oxford University, Oxford, UK
    Vaccine 31:670-5. 2013
    ....
  49. pmc Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Oxford, UK
    Mol Ther 20:1633-47. 2012
    ..Our findings offer the possibility of simplifying the deployment of viral vectors as a single mixture product rather than in heterologous prime-boost regimens...
  50. pmc Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study
    Stephen J Chapman
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Crit Care 14:R227. 2010
    ..The possible role of genetic variation in the atypical NF-κB inhibitor IκB-R, encoded by NFKBIL2, in susceptibility to invasive pneumococcal disease has not, to our knowledge, previously been reported upon...
  51. doi request reprint Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
    ..These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans...
  52. ncbi request reprint Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus
    Richard J Anderson
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 172:3094-100. 2004
    ..berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization. However, further improvement was not achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA...
  53. pmc Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A
    Kristin L Griffiths
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    PLoS ONE 6:e23463. 2011
    ..These results suggest a relationship between extracellular ATP and effector responses and unveil a possible pathway that could be targeted during vaccine design...
  54. pmc Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference
    Emily K Forbes
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    J Immunol 187:3738-50. 2011
    ..These data have important implications for the development of a multistage or multicomponent viral vectored malaria vaccine for use in humans...
  55. ncbi request reprint Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    J Infect Dis 191:619-26. 2005
    ..Forty-eight-hour growth rates in blood from control subjects were not different from those in blood from any vaccination group (mean, 14.4-fold [95% confidence interval, 11-19-fold])...
  56. pmc Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1
    Alexander D Douglas
    Jenner Institute, Oxford University, Oxford, UK
    Vaccine 28:7167-78. 2010
    ....
  57. pmc Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
    ..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care...
  58. doi request reprint A comparison of IFNgamma detection methods used in tuberculosis vaccine trials
    Natalie E R Beveridge
    Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
    Tuberculosis (Edinb) 88:631-40. 2008
    ..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved...
  59. ncbi request reprint Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  60. ncbi request reprint Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials
    Laura Andrews
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Am J Trop Med Hyg 73:191-8. 2005
    ..This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia...
  61. pmc Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    Geraldine A O'Hara
    Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
    J Infect Dis 205:772-81. 2012
    ..Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses...
  62. ncbi request reprint Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease
    Stephen J Chapman
    The Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    Mol Immunol 44:3267-70. 2007
    ..Although we are unable to exclude small effects of FCN2 genetic variation on susceptibility to IPD, the result suggests that L-ficolin may not be critical for host defence against pneumococcal infection...
  63. pmc The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming
    Stephen M Todryk
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford, UK
    Immunology 128:83-91. 2009
    ..This study highlights differences between CD4(+) and CD8(+) effector and memory T cells, and the more complex phenotype of CD4(+) T cells...
  64. ncbi request reprint Progress in DNA-based heterologous prime-boost immunization strategies for malaria
    Anne C Moore
    Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Immunol Rev 199:126-43. 2004
    ..We summarize the preclinical design and development of these heterologous prime-boost vaccines and discuss the encouraging results that have been observed in vaccinated humans...
  65. pmc Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  66. pmc The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom
    J Immunol 187:2602-16. 2011
    ....
  67. pmc A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e48322. 2012
    ..We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults...
  68. pmc Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    Patrick J Lillie
    Jenner Institute, University of Oxford, UK
    Clin Infect Dis 55:19-25. 2012
    ..Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers...
  69. pmc MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines
    Tamara K Berthoud
    University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, OX3 7LJ, UK
    J Immunol Methods 340:33-41. 2009
    ..Measurement of MIG alongside IFN-gamma may provide a fuller picture of Th1 type responses post-vaccination...
  70. pmc Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
    Matthew G Cottingham
    Wellcome Trust Centre for Human Genetics and The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1638. 2008
    ..Here we demonstrate in proof-of-concept experiments that MVA-BAC recombineering is a viable route to more rapid and efficient generation of new candidate mutant and recombinant vaccines based on a clinically deployable viral vector...
  71. doi request reprint Human genetic susceptibility to intracellular pathogens
    Fredrik O Vannberg
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Immunol Rev 240:105-16. 2011
    ..The results from these studies implicate common genetic variants in novel molecular pathways involved in human immunity to specific pathogens...
  72. pmc Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e22271. 2011
    ..Here we report the first study to examine the relationship between in vivo Plasmodium falciparum growth rates and in vitro GIA in humans experimentally infected with blood-stage malaria...
  73. ncbi request reprint Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value
    Frances Sanderson
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford, United Kingdom
    Am J Trop Med Hyg 78:878-83. 2008
    ..This finding may provide greater power to detect partial efficacy of many blood-stage candidate vaccines. We discuss the potential utility of blood-stage challenge studies in accelerating malaria vaccine development...
  74. ncbi request reprint Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis
    Graham S Cooke
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Am J Respir Crit Care Med 174:339-43. 2006
    ....
  75. ncbi request reprint Prime-boost strategies for malaria vaccine development
    Susanna J Dunachie
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    J Exp Biol 206:3771-9. 2003
    ..The prime-boost approach represents an encouraging step towards establishing an effective preventative vaccine to one of the world's greatest killers...
  76. ncbi request reprint IkappaB genetic polymorphisms and invasive pneumococcal disease
    Stephen J Chapman
    The Wellcome Trust Centre for Human Genetics, University of Oxford, and Oxford Centre for Respiratory Medicine, Churchill Hospital Site, Oxford Radcliffe Hospital, Roosevelt Drive, Oxford, OX3 7BN, UK
    Am J Respir Crit Care Med 176:181-7. 2007
    ..Rare NFKBIA mutations cause immunodeficiency with severe bacterial infection, raising the possibility that common IkappaB gene polymorphisms confer susceptibility to common bacterial disease...
  77. pmc Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, OX3 7LJ, UK
    Malar J 5:104. 2006
    ..Thick blood films are routinely used to diagnose Plasmodium falciparum malaria. Here, they were used to diagnose volunteers exposed to experimental malaria challenge...
  78. doi request reprint Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines
    Karen Colbjørn Larsen
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    Vaccine 27:5589-98. 2009
    ..These results indicate that optimal immunogenicity may require activation of distinct innate immune signalling pathways. Thus this strategy offers a novel route to the discovery of a new generation of adjuvants...
  79. pmc A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis
    Chiea C Khor
    The Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    Nat Genet 39:523-8. 2007
    ..6 x 10(-8)). We found that the Mal S180L variant attenuated TLR2 signal transduction...
  80. pmc Leprosy and the adaptation of human toll-like receptor 1
    Sunny H Wong
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    PLoS Pathog 6:e1000979. 2010
    ..These observations provide insight into the long standing host-pathogen relationship between human and mycobacteria and highlight the key role of the TLR pathway in infectious diseases...
  81. ncbi request reprint Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance
    Anne C Moore
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, United Kingdom
    J Immunol 175:7264-73. 2005
    ..Vaccine strategies incorporating anti-CD25 lead to improved protection against pre-erythrocytic malaria challenge. These data underpin new strategies for the design and development of more efficacious vaccines in clinical settings...
  82. pmc Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy
    Angela M Minassian
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e19840. 2011
    ..tb challenge. Translation of these findings to a human BCG challenge model could enable more rapid assessment and down selection of candidate TB vaccines and ultimately the identification of an immune correlate of protection...
  83. ncbi request reprint Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  84. ncbi request reprint A polymorphism that reduces RANTES expression is associated with protection from death in HIV-seropositive Ugandans with advanced disease
    Graham S Cooke
    Wellcome Trust Centre for Human Genetics, Churchill Hospital, University of Oxford, Oxford, United Kingdom, OX3 7BN
    J Infect Dis 194:666-9. 2006
    ....
  85. ncbi request reprint Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India
    Kerrie Tosh
    The Wellcome Trust Centre for Human Genetics, Oxford, UK
    Hum Mol Genet 15:2880-7. 2006
    ..The MICA*5A5.1 allele, associated here with leprosy susceptibility, encodes a protein lacking a cytoplasmic tail providing a possible mechanism for defective immune surveillance against mycobacteria...
  86. ncbi request reprint HIV in Africa (Communication arising): chemokine-receptor genes and AIDS risk
    Patricia A Ramaley
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Nature 417:140. 2002
    ..This gene may therefore not be subject to rapid evolutionary change as a result of the HIV epidemic in Africa...
  87. ncbi request reprint A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease
    William H H Reece
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Nat Med 10:406-10. 2004
    ..These findings provide direct evidence for a protective role for CD4(+) T cells in humans, and a precise target for the design of improved vaccines against P. falciparum...
  88. ncbi request reprint Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection
    Katie L Flanagan
    Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    Am J Trop Med Hyg 68:421-30. 2003
    ..This study provides important information regarding natural reactivity to a key malaria antigen...
  89. pmc Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial
    Fiona M Thompson
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1493. 2008
    ..This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle...
  90. ncbi request reprint Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
    Shahriar Behboudi
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DU, UK
    Vaccine 22:4326-31. 2004
    ..These data indicate that despite the ability of poxviruses to impair DC maturation in vivo, the important ability of MVA to boost CD8 T-cell response in vivo is mediated at the level of the infected dendritic cells...
  91. pmc Homozygosity and risk of childhood death due to invasive bacterial disease
    Emily J Lyons
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    BMC Med Genet 10:55. 2009
    ..Consequently, we performed a case-control study of fatal invasive bacterial disease in Kenyan children using a genome-wide screen with microsatellite markers...
  92. pmc Consanguinity and susceptibility to infectious diseases in humans
    Emily J Lyons
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Biol Lett 5:574-6. 2009
    ..Our results suggest that consanguinity is an important risk factor in susceptibility to infectious diseases in humans...
  93. ncbi request reprint MBL genotype and risk of invasive pneumococcal disease: a case-control study
    Suchismita Roy
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Lancet 359:1569-73. 2002
    ..We did a case-control study in the UK to assess whether these mutant genotypes were associated with invasive pneumococcal disease...
  94. ncbi request reprint Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families
    Alessandra C L Cervino
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Hum Mol Genet 11:1599-603. 2002
    ..002). These fine-mapping data suggest that UBE3A or a closely flanking gene may be a tuberculosis-susceptibility locus...
  95. ncbi request reprint CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans
    Tara Stanton
    Cancer and Immunogenetics Laboratory, Weatherall Institute of Molecular Medicine, Cancer Research UK, John Radcliffe Hospital, OX3 9DU, Oxford, UK
    Immunogenetics 56:107-10. 2004
    ..This suggests that the 54G variant and CD45 splicing abnormalities might be associated with HIV infection...
  96. ncbi request reprint Pre-erythrocytic malaria vaccines: towards greater efficacy
    Adrian V S Hill
    Centre for Clinical Vaccinology and Tropical Medicine, and The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Nat Rev Immunol 6:21-32. 2006
    ..This Review focuses on the potential immunological basis for the encouraging partial protection induced by these vaccines, and it considers ways for developing more effective malaria vaccines...
  97. ncbi request reprint Haptoglobin genotypes are not associated with resistance to severe malaria in The Gambia
    Christophe Aucan
    Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK
    Trans R Soc Trop Med Hyg 96:327-8. 2002
    ..No significant association was found between severe malaria and either haptoglobin genotypes or phenotypes. The advantages of using a deoxyribonucleic acid-based haptoglobin typing method are discussed...
  98. ncbi request reprint A region of chromosome 20 is linked to leprosy susceptibility in a South Indian population
    Kerrie Tosh
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    J Infect Dis 186:1190-3. 2002
    ..021), which suggests that a locus controlling susceptibility lies close to this marker...
  99. pmc Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
    Philip Bejon
    Kenya Medical Research Institute, Centre for Geographical Medicine Research Coast, Kilifi, Kenya
    PLoS ONE 2:e707. 2007
    ..5, 95% CI 1.0-2.3). Although the study was unblinded, another nine months follow-up was planned to monitor the incidence of malaria and other serious adverse events...
  100. ncbi request reprint Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara
    Nilu P Goonetilleke
    Nuffield Department of Clinical Medicine, Oxford University, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 171:1602-9. 2003
    ..These findings support further evaluation of mucosally targeted prime-boost vaccination approaches for tuberculosis...
  101. pmc Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes
    Eleftheria Zeggini
    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Science 316:1336-41. 2007
    ..The regions identified underscore the importance of pathways influencing pancreatic beta cell development and function in the etiology of type 2 diabetes...